Compositions and methods for treating lung inflammation
AssigneeaTyr Pharma, Inc.
InventorsJohn D. Mendlein, Kathleen Ogilvie
Life of this patent
Estimating the term…
Abstract
Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.
Claims12
A method of increasing serum concentration of a histidyl-tRNA synthetase (HRS)-Fc fusion polypeptide in a subject, comprising administering to the subject the HRS-Fc fusion polypeptide in combination with pirfenidone, wherein the HRS-Fc fusion polypeptide comprises, consists, or consists essentially of SEQ ID NO:
- 157.
Dependencies are inferred from the claim text.